C. Michael Gibson, MD, an interventional cardiologist at the Beth Israel Deaconess Medical Center in Boston, spoke with Cardiovascular Business about several trials presented during the European Society of Cardiology (ESC) Congress regarding new anticoagulants, especially what these new drugs could mean for U.S. atrial fibrillation and acute coronary syndrome patients, if they are approved.
Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
